Metastatic malignant neoplasm in the eye

Summary

Metastatic malignant neoplasm in the eye (MONDO:0044913) is a cancer. A subtype of ocular cancer — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	metastatic malignant neoplasm in the eye
Mondo ID	MONDO:0044913
NCIT	C4586
SNOMED CT	94292003
UMLS	C0347019
MedGen	91115
Anatomy (UBERON)	UBERON:0010230
Is cancer (heuristic)	yes

Also known as: eye metastasis · Metastases to eye · Metastases to the eye · metastasis to eye · metastasis to the eye · Metastatic malignant neoplasm in the eye · Metastatic malignant neoplasm to the eye · Metastatic neoplasm to the eye · Metastatic tumor to the eye · Metastatic tumour to the eye

Disease family

This is a subtype of ocular cancer. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › nervous system cancer › sensory system cancer › ocular cancer › metastatic malignant neoplasm in the eye

Related subtypes (9): lacrimal system cancer, eye carcinoma, uveal cancer, retinal cancer, conjunctival cancer, cornea cancer, eye lymphoma, ocular melanoma, eyelid cancer

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.